Eutox (botulinum toxin type A)
/ ATGC Co, EuBiologics
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 04, 2022
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
(clinicaltrials.gov)
- P3 | N=290 | Completed | Sponsor: EuBiologics Co.,Ltd | Active, not recruiting ➔ Completed
Head-to-Head • Trial completion
April 05, 2021
Phase 3 Study to Compare the Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
(clinicaltrials.gov)
- P3; N=290; Active, not recruiting; Sponsor: EuBiologics Co.,Ltd
New P3 trial
March 23, 2021
Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects
(clinicaltrials.gov)
- P1/2; N=60; Completed; Sponsor: EuBiologics Co.,Ltd; Active, not recruiting ➔ Completed
Clinical • Head-to-Head • Trial completion
1 to 3
Of
3
Go to page
1